通心络对AMI患者再灌注后心肌和微血管的保护性研究(1)
摘要：目的 研究通心络对急性心肌梗死患者再灌注后心肌和微血管的保护性。方法 选取2018年1月～2019年1月在我院治疗的成功实施PCI或溶栓治疗的急性心肌梗死患者94例，随机分为对照组和观察组，各47例。对照组采用常规药物治疗，观察组在对照组基础上联合通心络治疗，对比两组治疗后1周、2周、1个月室壁异常节段恢复率、左室舒张末容积(LVEDV)、左室射血分数(LVEF)、丙二醛(MDA)、一氧化氮(NO)等指标。结果 观察组治疗后1周、2周、1个月异常室壁运动节段恢复率均高于对照组(P<0.05);治疗后两组LVEF、LVEDV均较治疗前有改善，且观察组优于对照组(P<0.05);治疗后两组MDA均较治疗前降低，NO水平均较治疗前升高，且观察组优于对照组(P<0.05)。结论 通心络对急性心肌梗死患者再灌注后心肌和微血管具有良好的保护性，可减轻对患者心肌缺损再灌注损伤。
关键词：通心络;急性心肌梗死;微血管
中图分类号：R259;R541 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.11.051
, 百拇医药
文章编号：1006-1959(2019)11-0167-02
Abstract：Objective To study the protective effect of Tongxinluo on myocardial and microvessels after reperfusion in patients with acute myocardial infarction.Methods A total of 94 patients with acute myocardial infarction who underwent PCI or thrombolytic therapy in our hospital from January 2018 to January 2019 were randomly divided into the control group and the observation group，47 cases each. The control group received conventional drug therapy. The observation group was treated with Tongxinluo on the basis of the control group. The ventricular wall abnormality recovery rate， left ventricular end-diastolic volume (LVEDV)， and left ventricular ejection fraction were compared at 1 week， 2 weeks， and 1 month after treatment. (LVEF)， malondialdehyde (MDA)， nitric oxide (NO) and other indicators.Results The recovery rate of abnormal wall motion segment at 1 week， 2 weeks and 1 month after treatment was higher than the control group(P<0.05). After treatment， the LVEF of the both group were better than before treatment， and the observation group was superior to the control group(P<0.05). After treatment， the MDA of the both group were lower than before， the NO levels were higher than before， and the observation group was superior to the control group(P<0.05).Conclusion Tongxinluo has good protection against myocardial and microvessels after reperfusion in patients with acute myocardial infarction， which can alleviate myocardial defect reperfusion injury.
, 百拇医药
Key words：Tongxinluo;Acute myocardial infarction;Microvascular
急性心肌梗死(acute myocardial infarction，AMI)冠狀动脉早期血运重建，是心肌恢复再灌注的最有效方法。但是冠状动脉成功后，即使达TIMI Ⅲ级血流，仍有大约25%的患者并发无再流现象或慢血流现象，即不能真正有效的恢复心肌细胞的再灌注水平[1]。因此，减少缺血心肌-再灌注损伤，保持心肌微血管的完整性是有效改善缺血心肌、恢复心肌细胞功能的关键。但迄今尚无有关改善急性血管内皮损伤的特效药物。为此研究者将传统的中医理论和现代病机理论与复杂病理生理改变相结合，运用活血化癖学说和络病学说对此进行了量的研究工作，并取得了一定的疗效。研究显示通心络对再灌注后心肌和微血管具有良好的保护作用。本研究选取2018年1月～2019年1月我院治疗的94例成功实施PCI或溶栓治疗的急性心肌梗死患者临床资料进行研究，为临床的治疗提供一定参考，现报道如下。, 百拇医药(周立远)
关键词：通心络;急性心肌梗死;微血管
中图分类号：R259;R541 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.11.051
, 百拇医药
文章编号：1006-1959(2019)11-0167-02
Abstract：Objective To study the protective effect of Tongxinluo on myocardial and microvessels after reperfusion in patients with acute myocardial infarction.Methods A total of 94 patients with acute myocardial infarction who underwent PCI or thrombolytic therapy in our hospital from January 2018 to January 2019 were randomly divided into the control group and the observation group，47 cases each. The control group received conventional drug therapy. The observation group was treated with Tongxinluo on the basis of the control group. The ventricular wall abnormality recovery rate， left ventricular end-diastolic volume (LVEDV)， and left ventricular ejection fraction were compared at 1 week， 2 weeks， and 1 month after treatment. (LVEF)， malondialdehyde (MDA)， nitric oxide (NO) and other indicators.Results The recovery rate of abnormal wall motion segment at 1 week， 2 weeks and 1 month after treatment was higher than the control group(P<0.05). After treatment， the LVEF of the both group were better than before treatment， and the observation group was superior to the control group(P<0.05). After treatment， the MDA of the both group were lower than before， the NO levels were higher than before， and the observation group was superior to the control group(P<0.05).Conclusion Tongxinluo has good protection against myocardial and microvessels after reperfusion in patients with acute myocardial infarction， which can alleviate myocardial defect reperfusion injury.
, 百拇医药
Key words：Tongxinluo;Acute myocardial infarction;Microvascular
急性心肌梗死(acute myocardial infarction，AMI)冠狀动脉早期血运重建，是心肌恢复再灌注的最有效方法。但是冠状动脉成功后，即使达TIMI Ⅲ级血流，仍有大约25%的患者并发无再流现象或慢血流现象，即不能真正有效的恢复心肌细胞的再灌注水平[1]。因此，减少缺血心肌-再灌注损伤，保持心肌微血管的完整性是有效改善缺血心肌、恢复心肌细胞功能的关键。但迄今尚无有关改善急性血管内皮损伤的特效药物。为此研究者将传统的中医理论和现代病机理论与复杂病理生理改变相结合，运用活血化癖学说和络病学说对此进行了量的研究工作，并取得了一定的疗效。研究显示通心络对再灌注后心肌和微血管具有良好的保护作用。本研究选取2018年1月～2019年1月我院治疗的94例成功实施PCI或溶栓治疗的急性心肌梗死患者临床资料进行研究，为临床的治疗提供一定参考，现报道如下。, 百拇医药(周立远)